Market Survey Shows Potential of JAK Inhibitors to Treat IBD

Market Survey Shows Potential of JAK Inhibitors to Treat IBD
Directors from pharmaceutical and health insurance companies and gastroenterologists in the United States have expressed a positive opinion overall about the use of janus kinase (JAK) inhibitors for the treatment of inflammatory bowel disease (IBD), according to a recent survey. In the United States, TNF-α inhibitors, such as Remicade (infliximab) and Humira (adalimumab), are commonly used

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *